Earnings ·
Q32 Bio Inc. reported financial results for the quarter ended June 30, 2026, alongside a corporate update on its…
QTTBQ32 Bio Inc.
Q32 Bio Inc. reported financial results for the quarter ended June 30, 2026, alongside a corporate update on its bempikibart development program. The company announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial, showing a mean SALT score reduction of 35.3% and a 40.0% SALT-20 response rate in the mITT population. Q32 Bio completed a $200 million public offering in July 2026, bringing total cash resources to approximately $306.3 million as it prepares for a registration-directed program expected to initiate in the first half of 2027. For the quarter, the company reported a net loss of $8.9 million, or $0.44 per share, with research and development expenses at $4.3 million. Q32 Bio is a clinical-stage biotechnology company focused on developing therapies for alopecia areata and other autoimmune diseases.